Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes

February 23, 2017 updated by: Novo Nordisk A/S

Comparison of Efficacy and Safety of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes Mellitus

This trial is conducted in Asia and Oceania. The aim of this trial is to compare the efficacy and safety of human insulin produced by the current process and the NN729 process in type 1 diabetes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

241

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Dunedin, Australia, NZ
        • Novo Nordisk Investigational Site
      • Hamilton, Australia, NZ
        • Novo Nordisk Investigational Site
      • Kippa Ring, Australia, 4021
        • Novo Nordisk Investigational Site
      • Miranda, Australia, 2228
        • Novo Nordisk Investigational Site
      • Stones Corner, Australia, 4120
        • Novo Nordisk Investigational Site
    • New South Wales
      • Broadmeadow, New South Wales, Australia, 2292
        • Novo Nordisk Investigational Site
    • South Australia
      • Keswick, South Australia, Australia, 5035
        • Novo Nordisk Investigational Site
  • Hong Kong
      • Shatin, New Territories, Hong Kong
        • Novo Nordisk Investigational Site
  • Malaysia
      • Cheras, Malaysia, 56000
        • Novo Nordisk Investigational Site
      • Georgetown, Penang, Malaysia, 10450
        • Novo Nordisk Investigational Site
      • Kota Bharu, Kelantan, Malaysia, 16150
        • Novo Nordisk Investigational Site
  • Philippines
      • Cebu City, Philippines, 6000
        • Novo Nordisk Investigational Site
      • Iloilo, Philippines
        • Novo Nordisk Investigational Site
      • Makati City, Philippines, 1200
        • Novo Nordisk Investigational Site
      • Marikina City, Philippines, 1800
        • Novo Nordisk Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Duration of diabetes for at least 12 months
  • Basal/bolus treatment with human insulin for at least 2 months preceding trial start
  • Body Mass Index (BMI) lesser than or equal to 35.0 kg/m2
  • HbA1c lesser than or equal to 12.0%

Exclusion Criteria:

  • Proliferative retinopathy or maculopathy requiring acute treatment or laser treatment within the last 6 months
  • Any condition that the investigator and/or sponsor feel would interfere with trial participation
  • Known or suspected allergy against trial product or related products

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change of human insulin antibodies
Time Frame: after 26 weeks of treatment
after 26 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Frequency of adverse events
Change of human insulin antibodies

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2003

Primary Completion (Actual)

January 19, 2004

Study Completion (Actual)

January 19, 2004

Study Registration Dates

First Submitted

December 5, 2007

First Submitted That Met QC Criteria

December 6, 2007

First Posted (Estimate)

December 7, 2007

Study Record Updates

Last Update Posted (Actual)

February 27, 2017

Last Update Submitted That Met QC Criteria

February 23, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NN729-1541

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe